Toll-like receptor 4/nuclear factor-κB signaling pathway is involved in ACTG-toxin H-mediated anti-inflammatory effect

[1]  Q. Gu,et al.  Brevicompanine E reduces lipopolysaccharide-induced production of proinflammatory cytokines and enzymes in microglia by inhibiting activation of activator protein-1 and nuclear factor-κB , 2009, Journal of Neuroimmunology.

[2]  D. Shealy,et al.  Evaluation of anti-IL-6 monoclonal antibody therapy using murine type II collagen-induced arthritis , 2009, Journal of Inflammation.

[3]  D. Shao,et al.  Platonin inhibits LPS-induced NF-κB by preventing activation of Akt and IKKβ in human PBMC , 2008, Inflammation Research.

[4]  D. Meldrum,et al.  Differential IL-6 and VEGF secretion in adult and neonatal mesenchymal stem cells: role of NFkB. , 2008, Cytokine.

[5]  W. Yeh,et al.  LPS/TLR4 signal transduction pathway. , 2008, Cytokine.

[6]  A. Murakami,et al.  Targeting NOX, INOS and COX‐2 in inflammatory cells: Chemoprevention using food phytochemicals , 2007, International journal of cancer.

[7]  Q. Kang,et al.  Tricycloalternarene derivatives produced by an endophyte Alternaria alternata isolated from Maytenus hookeri , 2007, Journal of basic microbiology.

[8]  Robert E W Hancock,et al.  Complexities of targeting innate immunity to treat infection. , 2007, Trends in immunology.

[9]  M. Rafi,et al.  Glucosamine inhibits LPS-induced COX-2 and iNOS expression in mouse macrophage cells (RAW 264.7) by inhibition of p38-MAP kinase and transcription factor NF-kappaB. , 2007, Molecular nutrition & food research.

[10]  R. Carmody,et al.  Nuclear factor-kappaB: activation and regulation during toll-like receptor signaling. , 2007, Cellular & molecular immunology.

[11]  A. Hoffmann,et al.  Transcriptional regulation via the NF-κB signaling module , 2006, Oncogene.

[12]  B. Billack.  Macrophage activation: role of toll-like receptors, nitric oxide, and nuclear factor kappa B. , 2006, American journal of pharmaceutical education.

[13]  S. Abramson,et al.  Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. , 2006, Clinical immunology.

[14]  B. Kamińska.  MAPK signalling pathways as molecular targets for anti-inflammatory therapy--from molecular mechanisms to therapeutic benefits. , 2005, Biochimica et biophysica acta.

[15]  Ruslan Medzhitov,et al.  Toll-like receptors: linking innate and adaptive immunity. , 2005, Advances in experimental medicine and biology.

[16]  T. Kishimoto,et al.  Inhibition of IL-6 for the treatment of inflammatory diseases. , 2004, Current opinion in pharmacology.

[17]  V. Perry,et al.  Influence of the course of brain inflammation on the endogenous IL-1β/IL-1Ra balance in the model of brain delayed-type hypersensitivity response to bacillus Calmette–Guérin in Lewis rats , 2004, Journal of Neuroimmunology.

[18]  D. Golenbock,et al.  Human Cytomegalovirus Activates Inflammatory Cytokine Responses via CD14 and Toll-Like Receptor 2 , 2003, Journal of Virology.

[19]  P. Colville-Nash,et al.  COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease , 2000, The Lancet.

[20]  S. Akira,et al.  Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. , 1999, Immunity.

[21]  L. Pfeffer,et al.  NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase , 1999, Nature.

[22]  J. Nick,et al.  Activation of a p38 mitogen-activated protein kinase in human neutrophils by lipopolysaccharide. , 1996, Journal of immunology.

[23]  P. Isakson,et al.  Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. , 1996, The Journal of clinical investigation.

[24]  L Bibbs,et al.  A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. , 1994, Science.

[25]  S. Akira,et al.  TLR signaling. , 2006, Cell death and differentiation.

[26]  R. DuBois,et al.  Cyclooxygenase-2: a therapeutic target. , 2002, Annual review of medicine.

[27]  H. Bernstein,et al.  Reactive nitrogen species in colon carcinogenesis. , 1999, Antioxidants & redox signaling.

[28]  S. Moncada,et al.  Inhibition of nitric oxide synthase as a potential therapeutic target. , 1999, Annual review of pharmacology and toxicology.